FSHD 101 and research overview

Hanns Lochmüller

Children's Hospital of Eastern Ontario Research Institute Department of Medicine, The Ottawa Hospital Brain and Mind Research Institute, University of Ottawa











Disclosures


Consultancy or research support for research and clinical trials:

Amplo Biotechnology, AMO Pharma, argenx, Avidity, Biogen, Dyne, Fulcrum Therapeutics, Harmony Biosciences, Milo Biotechnology, Neurotune, NMD Pharma, Novartis, Pepgen, Pharnext, Pfizer, PTC Therapeutics, Hoffman-La Roche, Sanofi-Genzyme, Reveragen, Santhera, Sarepta, Satellos, Spark Therapeutics and Ultragenyx.


Investigator of sponsored clinical research (regulated trials) at CHEO and at TOH

Editor-in-chief of the Journal of Neuromuscular Disease (IOS Press)


FSHD is caused by ectopic expression of the germline transcription factor DUX4 in skeletal muscle cells.








Slides kindly provided by Dr Tawil, Rochester




Potential Therapeutic Targets



Challenges to Therapeutic development in FSHD

- Rare disease
- Slowly progressive*
- Wide spectrum of clinical severity
- Need new outcome measures that are more clinically relevant
- Need for biomarkers for early phase studies
 - MRI
 - Tissue biomarker



lochmullerlab.org





Thanks!







Special thanks to

- The Lochmüller lab and the CHEO-RI team in Ottawa
- Jeff Statland, Michaela Walker
- Fulcrum and Avidity for providing slides
- All investigators, staff and patients contributing to FSHD trials